For instance, Cabozantinib, a multikinase inhibitor that has inhibitory activity against Axl and other RTK, was approved as second and third line therapy for the treatment of advanced HCC after failure of sorafenib (126). The gene discussed is AXL; the disease is hepatocellular carcinoma.